Form 4: J&J Executive Mulholland Reports Routine Stock Transactions

Johnson & Johnson's EVP, Chief HR Officer Kristen Mulholland, filed a Form 4 detailing the vesting of equity awards and related tax withholdings.

Summary

• Kristen Mulholland, EVP, Chief HR Officer of Johnson & Johnson (JNJ), reported changes in her beneficial ownership of JNJ common stock.
• Transactions occurred on February 13, 2026, and February 15, 2026.
• Acquired 410 shares of common stock from Restricted Share Units (RSUs) vesting on February 13, 2026.
• Disposed of 135 shares at $244.55 for tax withholding related to the RSU vesting on February 13, 2026.
• Acquired 3,602 shares of common stock from Performance Share Units (PSUs) vesting on February 13, 2026.
• Disposed of 1,027 shares at $244.55 for tax withholding related to the PSU vesting on February 13, 2026.
• Acquired 419 shares of common stock from RSUs vesting on February 15, 2026.
• Disposed of 172 shares at $243.45 for tax withholding related to RSU vesting on February 15, 2026.
• Acquired 575 shares of common stock from RSUs vesting on February 15, 2026.
• Disposed of 251 shares at $243.45 for tax withholding related to RSU vesting on February 15, 2026.
• Received a new grant of 20,322 Employee Stock Options with an exercise price of $243.45, vesting in three equal annual installments starting February 15, 2027, and expiring February 15, 2036.
• Received a new grant of 1,459 Restricted Share Units (RSUs) vesting in three equal annual installments starting February 15, 2027.
• Following these transactions, Mulholland beneficially owns 19,830 shares of common stock directly, 418 RSUs, 1,150 RSUs, 1,459 RSUs, and 20,322 Employee Stock Options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting routine executive compensation activities that align management incentives with long-term shareholder value through new equity grants and the successful vesting of prior awards.

Positives

• Executive Kristen Mulholland received new grants of 20,322 Employee Stock Options and 1,459 Restricted Share Units, indicating continued long-term incentive alignment with shareholder interests.
• Vesting of previously awarded equity (RSUs and PSUs) demonstrates the successful achievement of performance or time-based conditions.

Negatives

• Shares were withheld for tax payments upon vesting, which is a common practice but reduces the immediate net share accumulation.

Future Outlook

The filing indicates future vesting events for newly granted Restricted Share Units and Employee Stock Options, with vesting scheduled in three equal annual installments beginning on the first anniversary of their February 15, 2026 grant date. The stock options are set to expire on February 15, 2036.

Industry Context

StockSavvy.ai notes that the reported transactions are routine executive compensation activities, including the vesting of long-term incentive awards and the grant of new equity, which are standard practices across large, publicly traded pharmaceutical and consumer health companies like Johnson & Johnson. These types of filings provide transparency into executive holdings and compensation structures, aligning management incentives with shareholder value over the long term.

Comparison to Industry Standards

• These transactions are consistent with typical executive compensation structures in the pharmaceutical and healthcare industry, where equity awards like RSUs, PSUs, and stock options are common tools for long-term incentive alignment.
• Companies such as Pfizer, Merck, and Abbott Laboratories frequently utilize similar equity-based compensation plans for their senior executives, with vesting schedules often tied to performance metrics or time-based service.
• The withholding of shares for tax purposes upon vesting is also a standard, non-discretionary practice.

Stakeholder Impact

• Shareholders: Provides transparency into executive equity holdings and compensation, reinforcing alignment of interests.
• Employees: Reflects standard executive compensation practices within the company.
• Executive (Kristen Mulholland): Represents the realization of long-term incentive compensation and the grant of new equity awards.

Next Steps

• First annual installment of new stock options and RSUs will vest starting February 15, 2027.
• Subsequent annual installments of new stock options and RSUs will vest over the following two years.
• Employee Stock Options will expire on February 15, 2036.

Key Dates

Keywords

Johnson & Johnson, JNJ, Form 4, Insider Transaction, Executive Compensation, Restricted Share Units, Performance Share Units, Stock Options, Equity Awards, Kristen Mulholland